Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05012618 · ClinicalTrials.gov registry record · Phase 1
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
A Phase 1 study, sponsored by Chugai Pharmaceutical.
- Terminated
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT05012618 is a Phase 1 study that was terminated before completion, run by Chugai Pharmaceutical. The registered enrollment target is 128 participants.
The verdict
NCT05012618, a Phase 1 study, was terminated before completion, sponsored by Chugai Pharmaceutical.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of LUNA18 when administered as a single agent or in combination with other anti-cancer drugs in patients with locally advanced or metastatic solid tumors.
Interventions
- DRUG Cetuximab
- DRUG LUNA18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2021-10-08 |
| Est. Completion | 2025-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05012618
The ClinicalTrials.gov registry entry for NCT05012618 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chugai Pharmaceutical, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT05012618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05012618 about?
NCT05012618 is a clinical study titled "A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).". This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of LUNA18 when administered as a single agent or in combination with other anti-cancer drugs in patients with locally advanced or metasta...
What is the current status of trial NCT05012618?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2021-10-08. Estimated completion is 2025-11-13.
What interventions are being tested in trial NCT05012618?
The interventions under investigation include: Cetuximab (DRUG), LUNA18 (DRUG).
Who is sponsoring clinical trial NCT05012618?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.